Company / Operating Income per Share
Sarepta Therapeutics Operating Income per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$7.22
FY2025
5-year range
-$7.22 / $2.33
FY2021-FY2025
Trend
-410.4%
vs FY2024
Sector context
#187 of 201
Health Care
What the data says
Operating Income per Share changed -410% YoY in FY2025, a notable deviation from the 9-year average annual change of -31%.
Based on SEC 10-K filings.
-7.22 in FY2025.
Declined from $-3.05 to $-7.22 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 201This company -$7.22 Sector average -$28.56
▼
+74.7% above sector average
Key checks
Key Insights
- In FY2025, operating income per share decreased 410.4% year-over-year.
- Ranks #187 out of 201 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$7.22 | -410.4% |
| FY2024 | $2.33 | +176.4% |
| FY2023 | -$3.05 | +53.0% |
| FY2022 | -$6.48 | -11.8% |
| FY2021 | -$5.79 | -26.7% |
| FY2020 | -$4.57 | -89.3% |
| FY2019 | -$2.41 | +54.5% |
| FY2018 | -$5.30 | -69.2% |
| FY2017 | -$3.13 | +46.4% |
| FY2016 | -$5.85 | -12.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026